ECCO News

ECCO News keeps ECCO Members up-to-date on what is going on within the organisation and reports on IBD activities taking place within Europe. Since Spring 2006, ECCO News has maintained the flow of information between Members of the organisation. 

ECCO News is an important part of the European Crohn’s and Colitis Organisation’s ambition to create a European standard of IBD care and to promote knowledge and research in the field of IBD. 

Editor & Associate Editors

Alessandro Armuzzi
© Alessandro Armuzzi

Nuha Yassin
© ECCO

Ignacio Catalán-Serra
© Ignacio Catalán-Serra

Brigida Barberio
© Brigida Barberio

Spyros Siakavellas
© Spyros Siakavellas

Latest ECCO News Content


27April2023

Takeda-sponsored symposia at the 18th ECCO Congress 2023, Copenhagen, Denmark

THIS SYMPOSIUM WAS SPONSORED BY TAKEDA



During the 18th ECCO Congress, Takeda collaborated with world-renowned experts to share practical tips for increasing treatment adherence, share key data, discuss new attitudes to treatment goals, and showcase real clinical experience. If you missed out on attending, then do not worry: you can read the highlights below and watch some of these sessions on-demand!  

Posted in ECCO News, ECCO'23, Volume 18, Issue 1

27April2023

Pfizer’s ECCO symposia highlights

THIS SYMPOSIUM WAS SPONSORED BY Pfizer Inc.



This March, the highly anticipated Pfizer symposia at ECCO 2023 delivered interesting, engaging, and thought-provoking updates for the treatment of patients with Ulcerative Colitis (UC).

The first of the two symposia took place on Thursday 2 March, as we asked delegates to join us at the crossroads in UC patient care. The ‘Choose your own path: UC patients at the crossroads’ symposium provided an engaging and interactive experience, led by distinguished faculty members Dr Peter Irving, Dr Joana Torres, Dr Maria T Abreu, and Dr Iris Dotan. Delegates entered the symposium hall to a rocking soundtrack from The Clash, Fleetwood Mac, Blondie, and Queen: a nod to the music stars’ top hits in each of the symposium presentation titles set the tone, looking to an upbeat future for patients with UC.

Posted in ECCO News, ECCO'23, Volume 18, Issue 1

27April2023

Diet in the management of IBD: Current status and future perspectives

This Symposium was sponsored by Nestlé Health Science



Introduction to Diets in the Management of IBD

Prof. Franck Carbonnel
Professor of Gastroenterology, University Paris Sud, France
Head, Gastroenterology Department, University Hospital of Kremlin Bicetre, Paris, France

In recent years, studies have shown the associations between food and the risks of developing Inflammatory Bowel Disease (IBD).

An early study showed a significant link between the consumption of red meat and the likelihood of developing Ulcerative Colitis (UC). Subsequent studies deepened our knowledge, pointing to associations between UC and a high consumption of omega-6, and low consumption of omega-3, fiber (fruit and vegetables), zinc and potassium.1,2,3,4,5,6,7,8,9

Other studies have shown a decreased risk of Crohn’s Disease (CD) in people who consume a larger proportion of unprocessed or minimally processed food, and an association between proinflammatory diets, ultra-processed foods, non-Mediterranean diet and CD.1-8,10,11,12,13,14

Posted in ECCO News, ECCO'23, Volume 18, Issue 1

27April2023

Meet the Reps: Israel - Interview with Bella Ungar & Ayal Hirsch

Ignacio Catalán-Serra, ECCO News Associate Editor

Ignacio Catalán-Serra
© I. Catalán-Serra

Dear ECCO friends,

Welcome to this wide-range conversation with the National Representatives of Israel at ECCO Bella Ungar and Ayal Hirsch, where we got to know more about IBD care in Israel and we discussed some hot areas of interest like: diet in IBD, new technologies and the need for multidisciplinary care and much more!

Hope you enjoy it!

Ignacio Catalán-Serra
ECCO News Associate Editor

Posted in ECCO News, Meet the Reps, Podcasts and Videos, Volume 18, Issue 1

27April2023

Meet the JCC Authors: Podcast with Mads Damsgaard Wewer

Nuha Yassin, ECCO News Associate Editor

Nuha Yassin
© Nuha Yassin

Dear ECCO friends and family,

Please join us for the 3rd episode of our podcast series Meet the JCC Authors!

It is my pleasure to introduce Mads Damsgaard Wewer from the University of Copenhagen, Denmark. He talks about the recently in JCC published paper: Disease Activity Patterns of Inflammatory Bowel Disease—A Danish Nationwide Cohort Study 1995–2018. We hope you enjoy getting to know Mads and learn more about his journal article.

Enjoy and do not forget to spread the word about our new podcast to your friends and colleagues!

Best Wishes,

Nuha Yassin

Consultant Colorectal Surgeon

ECCO News Associate Editor

Posted in ECCO News, Meet the JCC Authors, Podcasts and Videos, Volume 18, Issue 1

27April2023

Y-ECCO Interview Corner: Charlotte Hedin

Robin Dart, Y-ECCO Member

Robin Dart
© ECCO

The return of a physical ECCO Congress finally gave me the chance to interview people in person for ECCO News. So, after an early morning start, the outgoing Chair of Y-ECCO, Charlotte Hedin, and I sat down to talk about what led her into gastroenterology, the impact of moving country mid-career and the Y-ECCO Communication Toolbox, which has recently been made available on the ECCO e-Learning Platform.

Posted in ECCO News, Committee News, Volume 18, Issue 1, Y-ECCO

27April2023

Y-ECCO Literature Review: Dean Seah

Dean Seah

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): A randomised, double-blind, controlled, phase 2, proof-of-concept trial

Feagan BG, Sands BE, Sandborn WJ, et al.

Lancet Gastroenterol Hepatol 2023;8:307–20.


Dean Seah 
© Dean Seah 

Introduction

Despite a growing armamentarium of advanced therapies for Ulcerative Colitis (UC), fewer than 40% of patients maintain clinical remission at 12 months [1]. Combination therapy utilising dual biologic or small molecule agents can be considered in highly selected, medically refractory cases; however, robust data to support dual therapy in routine clinical practice are still lacking [2]. Inhibitors of TNF-α and IL-23 have demonstrated efficacy in the treatment of UC [3,4]. Data emerging from animal studies have suggested that their use in combination reduces colitis synergistically and may be more efficacious than treatment with either monotherapy [5].

This randomised double-blinded controlled phase 2 trial, named the VEGA trial, was conducted across 54 sites internationally and aimed to determine the efficacy and safety of combination therapy with guselkumab (GUS), an IL-23 p19 antagonist, plus golimumab (GOL), a TNF-α inhibitor, compared with either monotherapy in UC.

Posted in ECCO News, Y-ECCO Literature Reviews, Committee News, Volume 18, Issue 1, Y-ECCO

27April2023

Y-ECCO Literature Review: Andrea Centritto

Andrea Centritto

Point-of-care intestinal ultrasound in IBD patients: Disease management and diagnostic yield in a real-world cohort and proposal of a point-of-care algorithm

Bots S, De Voogd F, De Jong M, et al.

J Crohns Colitis 2022;16:606–615.


Andrea Centritto
© Andrea Centritto

Introduction

Intestinal ultrasound (IUS) is an inexpensive, non-invasive, safe and repeatable, dynamic cross-sectional imaging technique for IBD. It has been demonstrated to be accurate and reliable both for initial diagnosis of IBD and for follow-up monitoring [1]. Huge advantages of IUS are that it does not need any prior preparation of the patient and provides a real-time result. IUS can be performed in various hospital settings, which makes it the only point-of-care (POC) imaging technique available today [2].

The impact of POC IUS on daily decision making and the evolution in its use over the years were evaluated in this retrospective study, which included two consecutive cohorts of IBD patients in a real-world outpatient setting. The first cohort of patients, included between January 2016 and July 2018, was compared with a second cohort collected between October 2019 and December 2019.

Posted in ECCO News, Y-ECCO Literature Reviews, Committee News, Volume 18, Issue 1, Y-ECCO

27April2023

Y-ECCO Literature Review: Alice Moore

Alice Moore

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Louis E, Resche-Rigon M, Laharie D, et al; GETAID and the SPARE-Biocycle research group

Lancet Gastroenterol Hepatol 2023;8:215–27.


Alice Moore
© Alice Moore

Introduction

Therapeutic strategies for Crohn’s Disease have evolved over the past decade, with mounting evidence that achieving deep remission (defined as clinical, biochemical and endoscopic remission) is associated with better long-term outcomes [1, 2]. Combination therapy with infliximab and azathioprine has been shown to be superior to either infliximab or azathioprine monotherapy in achieving clinical remission and endoscopic healing in azathioprine-naive patients, thus supporting the paradigm of early disease management and the use of treatment combinations to increase treatment success [3]. Concerns regarding the implications of long-term combination therapy, such as infections and lymphoproliferative disorders, have provided the rationale for a formal clinical trial of treatment de-escalation.

The aim of this trial was to compare the relapse rate and the time spent in remission over 2 years between patients continuing combination therapy and those stopping infliximab or immunosuppressant therapy.

Posted in ECCO News, Y-ECCO Literature Reviews, Committee News, Volume 18, Issue 1, Y-ECCO

27April2023

Report on the 9th Y-ECCO Basic Science Workshop

Gabriele Dragoni, Y-ECCO Member


Gabriele Dragoni
© ECCO

After two consecutive virtual events, the Y-ECCO Basic Science Workshop was back with a face-to-face meeting, reaching its 9th edition on March 1, 2023, in Copenhagen.

This Workshop aims to involve young fellows in a fully comprehensive manner, giving them the opportunity to present relevant data that were submitted for the scientific programme and discuss their views with successful key opinion leaders in the field of Inflammatory Bowel Diseases (IBD), with special focus on basic and translational research. All sessions open with a hot topic presented by an invited senior specialist, followed by excellent presentations by selected young researchers. The secret of the constant success of this initiative is the friendly atmosphere, which allows participating Y-ECCO Members to increase their knowledge while also preparing for more challenging stages.

Posted in ECCO News, Committee News, Volume 18, Issue 1, Y-ECCO